drugset
Drugs / JAB-3312
last change Mar 2026 re-read 2 minutes ago

JAB-3312

also known as sitneprotafib
Developed for
non-small cell lung carcinoma · colorectal cancer · pancreatic ductal adenocarcinoma · breast cancer · esophageal squamous cell carcinoma · head and neck squamous cell carcinoma · acute myeloid leukemia, KRAS gene mutation
Investigated by
Allist Pharmaceuticals, Inc. · AbbVie · Jacobio Pharmaceuticals Co., Ltd.

Trials 5 · a red edge is where a trial was stopped

today NCT06416410 · Ph 3 NCT05288205 · Ph 1/2 NCT04720976 · Ph 1/2 NCT04121286 · Ph 1 NCT04045496 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04121286 Jul 2020 → Jun 2022 breast cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma +2 Allist Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1 NCT04045496 Sep 2019 → Dec 2022 breast cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma +2 Jacobio Pharmaceuticals Co., Ltd. Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05288205 Apr 2022 → Mar 2026 overdue acute myeloid leukemia, KRAS gene mutation, colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma Allist Pharmaceuticals, Inc. Recruiting No outcome recorded
Phase 1/2 NCT04720976 Mar 2021 → Dec 2023 non-small cell lung carcinoma Allist Pharmaceuticals, Inc. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT06416410 Aug 2024 → Sep 2026 expected non-small cell lung carcinoma Allist Pharmaceuticals, Inc. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as JAB-3312 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04121286 ↗
4

NCT04720976 ↗

NCT06416410 ↗

NCT05288205 ↗

NCT04045496 ↗
Known as sitneprotafib “We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway-targeted combination therapies.” PMID 40333694 ↗ Jul 2025
Action Inhibit “JAB-3312 (sitneprotafib), a potent inhibitor of SHP2” PMID 40333694 ↗ Jul 2025
Route Oral “JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.” NCT04045496 ↗